Literature DB >> 27350556

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.

M G Castagna1, S Cantara2, F Pacini2.   

Abstract

Radioactive iodine therapy is administered to patients with differentiated thyroid cancer (DTC) for eradication of thyroid remnant after total thyroidectomy or, in patients with metastatic disease, for curative or palliative treatment. In past years, thyroid remnant ablation was indicated in almost every patient with a diagnosis of DTC. Nowadays, careful revision of patients' outcome has introduced the concept of risk-based selection of patients candidate to thyroid remnant ablation. The present review aims to underline the indications for thyroid remnant ablation and to address methodologies to be employed.

Entities:  

Keywords:  Radioiodine; Thyroglobulin; Thyroid ablation; Thyroid cancer; rhTSH

Mesh：

Substances：

Year:  2016        PMID： 27350556     DOI： 10.1007/s40618-016-0503-z

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  77 in total

1.  Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.

Authors:  Ewa Ruel; Samantha Thomas; Michaela Dinan; Jennifer M Perkins; Sanziana A Roman; Julie Ann Sosa
Journal:  J Clin Endocrinol Metab       Date:  2015-02-02       Impact factor: 5.958

2.  Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.

Authors:  C Bal; A K Padhy; S Jana; G S Pant; A K Basu
Journal:  Cancer       Date:  1996-06-15       Impact factor: 6.860

3.  Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.

Authors:  Eleonora Molinaro; Carlotta Giani; Laura Agate; Agnese Biagini; Letizia Pieruzzi; Francesca Bianchi; Federica Brozzi; Claudia Ceccarelli; David Viola; Paolo Piaggi; Paolo Vitti; Furio Pacini; Rossella Elisei
Journal:  J Clin Endocrinol Metab       Date:  2013-04-26       Impact factor: 5.958

4.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

Authors:  Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners
Journal:  J Nucl Med       Date:  2006-04       Impact factor: 10.057

5.  Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.

Authors:  Edward B Silberstein
Journal:  J Nucl Med       Date:  2007-06-15       Impact factor: 10.057

6.  Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.

Authors:  M Chianelli; V Todino; F M Graziano; C Panunzi; D Pace; R Guglielmi; A Signore; E Papini
Journal:  Eur J Endocrinol       Date:  2008-12-12       Impact factor: 6.664

7.  Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen.

Authors:  I Borget; H Remy; J Chevalier; M Ricard; M Allyn; M Schlumberger; G De Pouvourville
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-02       Impact factor: 9.236

8.  A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients.

Authors:  Eyal Robenshtok; Ravinder K Grewal; Stephanie Fish; Mona Sabra; R Michael Tuttle
Journal:  Thyroid       Date:  2013-03-18       Impact factor: 6.568

9.  Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine.

Authors:  C J Edmonds; S Hayes; J C Kermode; B D Thompson
Journal:  Br J Radiol       Date:  1977-11       Impact factor: 3.039

10.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.

Authors:  Tania Pilli; Ernesto Brianzoni; Francesca Capoccetti; Maria Grazia Castagna; Sara Fattori; Angela Poggiu; Gloria Rossi; Francesca Ferretti; Elisa Guarino; Luca Burroni; Angelo Vattimo; Claudia Cipri; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2007-07-03       Impact factor: 5.958
View more
  7 in total

1.  Clinical and pathologic predictors of central lymph node metastasis in papillary thyroid microcarcinoma: a retrospective cohort study.

Authors:  C Y Gui; S L Qiu; Z H Peng; M Wang
Journal:  J Endocrinol Invest       Date:  2017-09-07       Impact factor: 4.256

2.  Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies.

Authors:  F Pacini; F Basolo; R Bellantone; G Boni; M A Cannizzaro; M De Palma; C Durante; R Elisei; G Fadda; A Frasoldati; L Fugazzola; R Guglielmi; C P Lombardi; P Miccoli; E Papini; G Pellegriti; L Pezzullo; A Pontecorvi; M Salvatori; E Seregni; P Vitti
Journal:  J Endocrinol Invest       Date:  2018-05-04       Impact factor: 4.256

3.  Clinicopathological features of thyroid cancer in the elderly compared to younger counterparts: single-center experience.

Authors:  F D Dellal; D Özdemir; A A Tam; H Baser; H Tatli Dogan; O Parlak; R Ersoy; B Cakir
Journal:  J Endocrinol Invest       Date:  2016-11-24       Impact factor: 4.256

4.  Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome.

Authors:  G Sapuppo; F Palermo; M Russo; M Tavarelli; R Masucci; S Squatrito; R Vigneri; G Pellegriti
Journal:  J Endocrinol Invest       Date:  2017-06-23       Impact factor: 4.256

5.  Clinicopathologic risk factors for right paraesophageal lymph node metastasis in patients with papillary thyroid carcinoma.

Authors:  Q A Yu; D K Ma; K P Liu; P Wang; C M Xie; Y H Wu; W J Dai; H C Jiang
Journal:  J Endocrinol Invest       Date:  2018-03-17       Impact factor: 4.256

6.  Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor.

Authors:  M G Castagna; R Forleo; F Maino; N Fralassi; F Barbato; P Palmitesta; T Pilli; M Capezzone; L Brilli; C Ciuoli; S Cantara; C Formichi; F Pacini
Journal:  J Endocrinol Invest       Date:  2018-02-22       Impact factor: 4.256

7.  Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary thyroid carcinoma: a population-based study.

Authors:  Jinkui Wang; Chenghao Zhanghuang; Liming Jin; Zhaoxia Zhang; Xiaojun Tan; Tao Mi; Jiayan Liu; Mujie Li; Xin Wu; Xiaomao Tian; Dawei He
Journal:  BMC Geriatr       Date:  2022-09-08       Impact factor: 4.070
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.